CBLL earnings analysis
What we found in CBLL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Ceribell delivered strong top-line momentum in Q2 2026, with revenue of $28.097 million and gross margin of 92.0%, and raised full-year revenue guidance to $114 million-$117 million. However, EPS was a loss of $0.51, the company reported a six-month net loss of $39.0 million, and operating profitability was not disclosed in the supplied filing extract. The new $20.0 million secured revolver, minimum revenue or cash covenant, ongoing Natus litigation, and evolving QMSR requirements temper the otherwise favorable revenue and margin trend.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth accelerated
- Second-quarter revenue was $28.097 million, up from $21 million in 2025 Q2 and $26 million in 2026 Q1; the result exceeded consensus revenue of $27.268 million by approximately 3.0%.
- Gross margin expanded
- Gross margin improved to 92.0% from 88.1% in 2025 Q2 and 87.3% in 2026 Q1, indicating substantially stronger unit economics.
- Full-year outlook raised
- Full-year 2026 revenue guidance increased to $114 million-$117 million from the prior $112 million-$116 million range.
- New Medicare reimbursement support
- CMS granted an NTAP designation for the Delirium Monitor System effective October 1, 2026, potentially improving reimbursement support for eligible Medicare cases.
- Controls remained effective
- Management stated that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026, with no material changes to internal control over financial reporting during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Persistent losses and accumulated deficit
- The company incurred a net loss of $39.0 million for the six months ended June 30, 2026, and had an accumulated deficit of $259.4 million as of that date. The filing states that substantial additional losses are expected in the foreseeable future.
- New secured debt and covenants
- On August 5, 2026, the company borrowed $20.0 million under a new revolving facility to repay the VLSA. The Credit Agreement is secured by substantially all assets, including intellectual property, and may require minimum trailing-12-month net revenue of $70.0 million or unrestricted cash of $65.0 million when the covenant is effective.
- Patent litigation remains pending
- The Natus patent case remains unresolved: USITC trial proceedings concluded June 12, 2026, an initial determination is expected by November 19, 2026, and a final determination by March 2027. The company has requested an exclusion order and a permanent injunction, while litigation expenses and an adverse outcome remain risks.
- Higher medical-device compliance burden
- The filing identifies the FDA's QMSR as effective February 2, 2026. Although the company states its quality system is designed to comply with ISO 13485, ISO certification alone does not ensure QMSR compliance, potentially increasing regulatory compliance costs.
- China and Vietnam supply-chain exposure
- The company relies on two primary contract manufacturers in China and contractors in China for monitoring and quality inspection, while also using suppliers in Vietnam. The filing warns that tariffs, trade restrictions and geopolitical tensions could increase costs and disrupt supply.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.51
- Gross margin
- 92.0%
What they said about what is next.
Full-year 2026 revenue outlook was raised to $114 million-$117 million from $112 million-$116 million, reflecting continued momentum from new account additions and increased utilization.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- Ceribell's Q1 2026 results revealed stronger-than-expected revenue of $26.5 million, surpassing estimates of $26.1 million, despite a deeper-than-anticipated loss per share of $0.52 compared to the expected loss of…
- 10-K · February 24, 2026
- Ceribell describes a focused strategy to become the standard of care for acute-care seizure detection by scaling adoption of its Ceribell System, expanding indications (FDA 510(k) for delirium in Dec 2025) and investing…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CBLL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever